CERO THERAPEUTICS HOLDINGS, INC.
CEROOTCHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | — | −$897,133 | −$7.7M | −$2.9M | — |
| Net income | −$19.9M | −$572,211 | −$7.3M | −$667,736 | −$315,547 |
| Total assets | $3.6M | $6.2M | $5.1M | $42.4M | $180.1M |
| Total liabilities | $9.1M | $8.1M | $5.1M | $39.9M | $9.2M |
| Equity | −$5.4M | −$2.3M | −$42.1M | −$11.0M | −$7.7M |
| EPS (diluted) | — | $-97.90 | $-1248.64 | — | — |
| Shares out. | 5.4M | 14.7M | 5,845 | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 365.7%
- Return on assets
- −547.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 249.6%
- Debt / equity
- —
- Book value / share
- $-1.01
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −104.9%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 17, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tibbs IsaiahPassive (13G)Mar 12, 2026
- Armistice Capital, LlcPassive (13G)Aug 14, 2025
- Atwood Brian GActivist (13D)Apr 4, 2025
- Yk Bioventures Opportunities Gp I, LlcPassive (13G)Dec 17, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 28,198 | 1.0 | -75.0% |
| Apr 30, 2026 | 112,724 | 1.0 | +1007.1% |
| Apr 15, 2026 | 10,182 | 1.0 | -79.4% |
| Mar 31, 2026 | 49,526 | 1.0 | -10.3% |
| Mar 13, 2026 | 55,225 | 1.0 | +5362.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligation · Unregistered equity saleMay 29, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleMay 1, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleApr 14, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleMar 11, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Changed auditor · Director / officer changeFeb 13, 2026
- Other material eventFeb 4, 2026
- Delisting / listing-standard noticeFeb 3, 2026
- Regulation FD disclosure · Other material eventJan 7, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 424B3PROSPECTUS SUPPLEMENTMay 29, 2026
- 8-KCURRENT REPORTMay 29, 2026
- 424B3PROSPECTUS SUPPLEMENTMay 15, 2026
- 10-QQUARTERLY REPORTMay 15, 2026
- 424B3PROSPECTUS SUPPLEMENTMay 1, 2026
- 8-KCURRENT REPORTMay 1, 2026
- 424B3PROSPECTUS SUPPLEMENTMay 1, 2026
- 10-K/AAMENDMENT NO. 1 TO FORM 10-KApr 30, 2026
- 4Apr 21, 2026
- 3Apr 21, 2026
- 424B3PROSPECTUS SUPPLEMENT NO. 8Apr 15, 2026
- 10-KANNUAL REPORTApr 15, 2026
- 424B3PROSPECTUS SUPPLEMENTApr 14, 2026
- 8-KCURRENT REPORTApr 14, 2026
- NT 10-KNOTIFICATION OF LATE FILINGApr 1, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.